MM&M and PRWeek editors convened to select 50 battle-tested pros who are changing the healthcare game. Find out if you made the list.
Here you'll find everything you need to know from MM&M's 50th anniversary issue, including the story behind Viagra, the death of tchotchkes, and much more.
The experimental therapy is positioned to fill a market gap in primary progressive multiple sclerosis.
MS drugs top the list, led by Teva's Copaxone, Biogen's Tecfida and Avonex, and Novartis' Gilenya.
The neurology market is again attracting attention and investment from various — and at times unexpected — corners of the biopharma industry.
Millian, a former Sanofi and Merck executive, on marketing new therapies in the MS market.
The chief creative officer at Carling Communications talks about how she learned that the best leaders are only as good as the performance of their team.
Ad pushes behind brands like Gilead Sciences' hepatitis-C pill Harvoni and Allergan's IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. Cancer drugs once again were the hottest category.
Here, you'll find everything you need to know about MM&M's 2016 Career and Salary Survey, including data on salaries and agency employment trends.
The agency's ambitions were fueled in part by external criticism. The barbs that stung most sharply were ones suggesting a certain indifference on the FDA's part.
When drug costs started to soar, PBMs turned to formulary exclusions — and the industry is still feeling the pinch.
Given its modern-day ubiquity, it's easy to forget that pharma DTC didn't exist until the 1980s rolled around.
The inside story on a campaign for the ages, as told by the individuals who worked on it.
Did you know that Norman Rockwell was a medical illustrator for Merck?
For some people in the industry ecosystem, the appeal of promo knickknacks endures.
And why the stories behind thalidomide, Naprosyn, AZT, cardiology stents, and Zaltrap still resonate.
The vice president of audience development talks about her days in the dot-com world and how struggling in a new role shaped her career.
They share their insights, secrets, worries, and everything else in between.
Hint: it pays to be an EVP.
"It's easy to 'fill open positions,'" Marchese says. "We've banned that phrase. If you do that, you're just checking boxes on a list."
Execs say that career prospects are better than ever. Yet data from MM&M's annual Career and Salary Survey reveals a decline in growth.
The intersection of data, technology, and medicine is rapidly changing how doctors practice, drug companies market, and patients engage with the healthcare system.
The availability of online medical information is changing the way doctors share and receive information — both among themselves and with their patients.
Diabetes is one of the most stubborn conditions to treat effectively. Drugmakers are turning to machine learning, online coaching, and gamification.
Will this payer pressure pose an existential threat to co-pay cards even though patients love them?
Fueled by innovation in new treatments, the underserved women's health market has begun to turn the proverbial corner. What took it so long?
Amgen's osteoporosis drug Prolia is the category leader, projected to bring in $992 million in sales in 2016.
The osteoporosis drug market is bracing for the advent of potentially game-changing treatments.
Only one new osteoporosis drug has been approved over the last six years.
Read about MM&M's inaugural Hall of Femme event and the rest of the MM&M August issue.
The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.
Read the 2016 Agency Issue in its entirety.
It's unlikely that pharma will ever achieve the degree of consumer love directed at Amazon and Apple but the shift taking place will open up doors for pharma organizations.
A story about a boss giving away a woman's bonus to a man based on his breadwinning status resonated with Hall of Femme attendees.
McCann Health, the 2016 Lions Health Network of the Year, and Campaign invited top marketers and visionary artists to discuss creativity during this year's Lions Health festival.
Twitter's health team offers advice on how pharma and healthcare companies can more effectively utilize 140 characters.
Type 2 diabetes is on the rise, around the world. The IMS Institute for Healthcare Informatics breaks down diabetes prevalence in Brazil, Mexico, Saudi Arabia, the U.K., and the U.S.
Baby boomers have taken to health tech with surprising ease, opening up a wealth of opportunities for marketers savvy enough to pursue them.
While analysts predict a first-in-class appearance before the FDA by 2018, many obstacles have arisen.
Despite the arrivals of new drugs, Genentech continues to be the market leader. Its drugs, Rituxan, Avastin, and Herceptin, are the category leaders, generating a total of $9.29 billion in sales.
Interest in oncology is on the rise as the blockbuster drug era breathes its last, and this has altered marketing in cancer care.
Avanir's success with Nuedexta sparked the attention of several suitors. In 2014 the company reached a deal to be sold to Otsuka Pharmaceutical for around $3.5 billion
Read the 2016 June issue in its entirety.
Visions, challenges, and advice: Here are 100 quotes from 100 agency leaders, compiled from the MM&M Agency Issue.
Five executives from the industry's largest holding companies discuss their move away from the traditional network structure.
A number of mergers and acquisitions among healthcare agencies in 2015 and 2016 changed the landscape.
Healthcare agencies focus on freeing pharma brands from their collaboration cocoons to work with health tech companies, while squaring away access concerns.
The co-founder of Mapquest.com talks about his move from online mapping to healthcare, and what he likes most meeting with clients.
The chief planning officer of North America talks about strategy and how to tell an engaging health story.
Despite the increasing importance of the CIO post, top technology professionals still find it hard to break into the uppermost ranks at life-sciences companies.
Drugmakers and tech companies are developing wearables and using popular fitness trackers like the Fitbit in clinical trials to gain insights about Parkinson's Disease.
In partnership with inVentiv Health, MM&M found a millennial doctor to ask about her frustrations with the existing pharma marketing model to her willingness to text patients.
Besides being the right thing to do, elevating woman leaders confers a competitive edge to companies, a fact confirmed by multiple studies.
Although telehealth is still in its early stages, it's building momentum — with good reason.
Here, see side-by-side comparisons of the drugs spending on advertising, approval dates, and 2015 sales figures.
A Sermo poll asked physicians: Do you feel biosimilars will prove safe and effective enough for you to prescribe them when more become available?"
Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.
Why would any CEO tolerate a corporate culture that holds people back?
It's a common refrain in healthcare and among patients, providers, and payers: Despite massive investment, no one has figured out how to change human behavior.
To no surprise, Gilead Sciences' Harvoni and Sovaldi were the top-selling infectious disease products in 2015.
The goal is to develop medications that move beyond the high-toxicity and low-efficacy profiles of older drugs.
Even as Gilead prepares to launch a third hepatitis-C product, drugs offering better antimicrobial resistance are angling for their own moments in the spotlight.
AbbVie's Humira is the top selling autoimmune drug in 2015, bringing in $10.6 billion in sales in the U.S. alone.
The bar for market success has been set high for baricitinib.
Drugmakers are working toward developing drugs in lupus, celiac disease, and other conditions that have rarely captured their attention in the past.
Learn more about the top therapeutic categories by sales, top companies by revenue, top drugs by sales, and more.
The index of the top 20 drugmakers from the 2016 pharma report.
Immuno-oncology was the story at Bristol-Myers Squibb in 2015.
So, heard anything lately about Valeant? Yeah. Even by the standards of an industry under siege, Valeant experienced quite the tumultuous last year or so.
Biogen's 2015 was hindered by less-than-stellar sales of its flagship multiple sclerosis treatment Tecfidera.
After turning its back on an offer from generics competitor Teva, Mylan stepped up with an unsuccessful hostile takeover bid for generic drugmaker Perrigo.
In an effort to overcome pricing pressures and bounce back from patent losses, Germany's second-largest drugmaker has unloaded assets and reshuffled its management team.
The year 2015 was one of restructuring for GlaxoSmithKline.
Novo Nordisk wants to own the obesity space much in the same way that it has attempted to dominate diabetes.
Diabetes drugs headlined Eli Lilly's 2015 results, with Humalog and Trulicity contributing mightily to the upward sales curve.
Coming off what AbbVie's board dubbed an "exceptional year," 2016 may sting.
Allergan and Pfizer agreed to scrap their pending mega-merger following an early April power play by the U.S. government.
The big news: Sanofi and its partner Regeneron received approval for the first PCSK9 inhibitor to come to market in the U.S.: Praluent. But Praluent's sales to date haven't awed analysts.
On the sales and profit forecast front, analysts say that Roche missed the mark in 2015.
As Amgen executives continue to toast a spectacular 2015 performance — double-digit growth from five of eight blockbusters — CEO Robert Bradway has cast a keen eye on the biotech pioneer's future.
Analysts agree that Teva is casting a healthy financial shadow.
Total medicine spending surged to $424.8 billion in 2015, representing an increase of 12.2%. Here's why that growth figure is closer to 2.9%.
Mere days after the Pfizer deal collapsed, top Allergan executives had nary an air of regret about them.
AstraZeneca has embarked on what's likely to be a long, rough ride.
Pfizer's dream to shave the top off a rising U.S. tax bill — and level the playing field with overseas competitors — was dashed.
There are two primary reasons Novartis anticipates flat sales during 2016: Its hallmark cancer drug Gleevec recently came off patent and its Alcon ophthalmic business has seen declining growth rates.
Merck's landmark approval in 2015 was for immunotherapy Keytruda, which was cleared in October as a second-line treatment for the most common form of skin cancer.
J&J has earmarked a pile of cash — in the neighborhood of $18.5 billion — for future acquisition targets, but is patiently pacing the sidelines for the best players to walk onto the field.
Gilead's current and future success lies in the hands of its antiviral franchise.
- Sunovion hires former BI exec as VP of marketing
- Five things for pharma marketers to know: Tuesday, October 25, 2016
- Five things for pharma marketers to know: Monday, October 24, 2016
- Five things for pharma marketers to know: Wednesday, October 26, 2016
- If Roche's Ocrevus is approved, the already competitive MS market will gain another player
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy